Glass, Joseph E. http://orcid.org/0000-0002-2923-3698
Dorsey, Caitlin N.
Beatty, Tara
Bobb, Jennifer F.
Wong, Edwin S.
Palazzo, Lorella
King, Deborah
Mogk, Jessica
Stefanik-Guizlo, Kelsey
Idu, Abisola
Key, Dustin
Fortney, John C.
Thomas, Rosemarie
McWethy, Angela Garza
Caldeiro, Ryan M.
Bradley, Katharine A.
Funding for this research was provided by:
National Institute on Drug Abuse (R01DA047954)
National Institute on Alcohol Abuse and Alcoholism (K01AA023859)
Article History
Received: 18 November 2022
Accepted: 22 December 2022
First Online: 1 February 2023
Declarations
:
: The Kaiser Permanente Washington Institutional Review Board granted ethical approvals. The primary data collection for the economic evaluation was determined to be exempt from review. A waiver of documentation of consent was granted for health coaching. Waivers of consent were granted to randomize clinics, and to access, use and collect data for the formative evaluation, practice facilitation, and quantitative evaluation because the study was deemed to have no more than minimal risks and it would not be otherwise feasible to conduct the study.
: Not applicable.
: Pear Therapeutics Inc provided digital therapeutic prescriptions at no cost to Kaiser Permanente Washington during a quality improvement pilot study that preceded this implementation trial. During the current trial, the study’s National Institutes of Health grant (R01DA047954) pays Pear Therapeutics for digital therapeutic prescriptions and other support. JEG is a coinvestigator on a Small Business Innovation Award funded awarded to Pear Therapeutics, Inc by the National Institute on Drug Abuse, which evaluates potential improvements to reSET-O (R44DA042652). Pear Therapeutics does not provide funding to the authors.